JAN 30, 2019 4:33 PM PST

Targeting Transplant Rejection

WRITTEN BY: Nicholas Breehl

Bone marrow transplant (BMT) offers patients with leukemia and lymphoma a potentially curative treatment. Bone marrow from the donor contains healthy immune cells (T cells and B cells), whose mission is to protect the body from invaders. These immune cells can target the recipient's cancer cells, helping protect against tumor relapse.

This procedure, however, is not without risk. T cells can also recognize the recipient's tissues as foreign and attack them. This phenomenon, known as graft-vs-host disease (GVHD), can cause severe complications in transplant recipients, significantly reducing their quality of life.

The standard procedure to prevent GVHD is to treat patients with drugs that suppress T cells. However, this makes patients more susceptible to infections and increases the risk of tumor relapse. Even with this therapy, 30 to 50 percent of patients develop acute GVHD, and about 70 percent develop some degree of chronic GVHD.

"GVHD can be expected to occur in the majority of transplanted patients," says Xue-Zhong Yu, M.D., professor of Microbiology and Immunology in the College of Medicine at the Medical University of South Carolina (MUSC) and SmartState Endowed Chair in Cancer Stem Cell Biology and Therapy at Hollings Cancer Center. "More treatment options are desperately needed."

Yu led a team of MUSC researchers who showed that targeting the enzyme Sirt-1 helped control GVHD in mice, without increasing tumor relapse. They reported their findings in an article published online December 4, 2018, by Blood. In BMT models, mice that received a Sirt-1 inhibitor lived longer and had better clinical scores than those that did not. This effect appears to be mediated through T cells.

"What's exciting about our study is that Sirt-1 regulates different subsets of T cells differently," says Yu. "So by inhibiting it, we can suppress T cells that lead to GVHD without affecting those that protect against tumor relapse. Also, blocking Sirt-1 could be effective in preventing both acute and chronic GVHD."

Acute and chronic GVHD are very different diseases, distinguished primarily by the time of onset and clinical manifestations. Acute GVHD occurs during the first months after transplant, while chronic GVHD reduces the long-term quality of life of patients.

Although treatment options have improved for acute GVHD, chronic GVHD remains a therapeutic dilemma. It causes widespread scarring (fibrosis) of the organs affected, leading to loss of organ function. In this study, blocking Sirt-1 showed a positive effect, even after chronic GVHD had developed.

In chronic GVHD, B cells are activated (triggered to grow) and differentiated (specialized in their immune function). Sirt-1-deficient T cells reduced B cell activation and differentiation in chronic GVHD mouse models.

"This indicates that Sirt-1 plays an important role in T- and B- cell interaction in GVHD development," says Anusara Daenthanasanmak, Ph.D., who was a postdoctoral fellow in the Yu lab while doing this work and is now at the National Institutes of Health. "By blocking Sirt-1 activity, we could have a potential treatment for both acute and chronic GVHD."

Yu's lab is interested in exploring further the role of Sirt-1 in the regulation of B cells. "B cells are critical in the pathogenesis of chronic GVHD," says Yu. "That is still a gap we need to fill in."

Although the preclinical results are robust, much needs to be done before they can affect patient care.

"I hope to be able to translate the findings in my lab to the clinic," says Yu. "But, first, further studies are needed to examine the role of Sirt-1 in human T cells and a human setting, assessing correlations in patients."

Sources: Science Daily, American Society of Hematology, YouTube

 

About the Author
You May Also Like
AUG 11, 2020
Immunology
Study Reveals the Two Sides of an Immune Molecule
AUG 11, 2020
Study Reveals the Two Sides of an Immune Molecule
Scientists have discovered a key protein that regulates the immune system to fight off infections. Fascinatingly, the pr ...
AUG 12, 2020
Immunology
Is Gluten Becoming More Immunoreactive?
AUG 12, 2020
Is Gluten Becoming More Immunoreactive?
In recent years, the number of people diagnosed with celiac disease has increased drastically, even with many undiagnose ...
SEP 28, 2020
Genetics & Genomics
Why Some Young, Healthy People Get Severe COVID-19
SEP 28, 2020
Why Some Young, Healthy People Get Severe COVID-19
Since the start of the pandemic, scientists have been trying to find out why some people get such severe illness from SA ...
OCT 06, 2020
Drug Discovery & Development
New Immunotherapy Drug Effective Against Lung Cancer
OCT 06, 2020
New Immunotherapy Drug Effective Against Lung Cancer
A new study has confirmed that Tecentriq, an immunotherapy drug, improves survival rates among those with newly diagnose ...
OCT 28, 2020
Microbiology
Immune Cells Link Gum Disease to Inflammatory DIsorders
OCT 28, 2020
Immune Cells Link Gum Disease to Inflammatory DIsorders
Scientists and clinicians know that oral health and inflammation, which is a part of many diseases, are connected.
NOV 16, 2020
Immunology
Measles Is Back and COVID Isn't Helping
NOV 16, 2020
Measles Is Back and COVID Isn't Helping
Measles is a highly contagious and airborne viral disease. There is no treatment besides supportive care once a person b ...
Loading Comments...